(Q35067640)

6 August 2017

1 reference

title

Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability (English)

1 reference

6 August 2017

author name string

Jonathan S E Hellewell

series ordinal

1

1 reference

6 August 2017

language of work or name

1 reference

1 December 2002

1 reference

Journal of Affective Disorders

6 August 2017

published in

1 reference

6 August 2017

volume

72 Suppl 1

1 reference

6 August 2017

page(s)

S23-34

1 reference

Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Carbamazepine in manic-depressive illness: a new treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

The effect of oxcarbazepine on behavioural despair and learned helplessness.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Perspectives on the use of anticonvulsants in the treatment of bipolar disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Carbamazepine compared to haloperidol in acute mania

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Memory and psychomotor effects of oxcarbazepine in healthy human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Oxcarbazepine in affective and schizoaffective disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Lithium versus carbamazepine in the maintenance treatment of bipolar disorders--a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Incidence and significance of mixed affective states in a bipolar population

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Basic haematological parameters, serum gamma-glutamyl-transferase activity, and erythrocyte folate and serum vitamin B12 levels during carbamazepine and oxcarbazepine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Carbamazepine, lithium, and life course of bipolar affective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

The treatment of affective disorder with carbamazepine: Prophylactic synergism of lithium and carbamazepine combination

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Use of carbamazepine in acute psychosis: a controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Carbamazepine vs lithium in the treatment and prophylaxis of mania

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: A double-blind controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Effects of carbamazepine and lithium on affective disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Antidepressant effects of carbamazepine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

The place of anticonvulsant therapy in bipolar illness

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Correlates of antimanic response to carbamazepine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Comparison of oxcarbazepine and carbamazepine: a double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Mania. Diagnosis, state measurement and prediction of treatment response

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Lithium treatment of mania: clinical characteristics, specificity of symptom change, and outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

The effect of carbamazepine and lithium on remission from affective illness

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

Oxcarbazepine: an update of its efficacy in the management of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2802%2900338-5

7 January 2021

10.1016/S0165-0327(02)00338-5

Identifiers

DOI

1 reference

6 August 2017

1 reference